

APPENDIX A - "Marked-up" Versions of Amended Claims as Required Under
37 C.F.R. 1.121(c)(1)(ii)

13. (Amended) A composition comprising a variant HBV or variant HbsAg according to any one of claims 1 to 12 [or a recombinant or derivative form or its chemical equivalent] and one or more pharmaceutically acceptable carriers and/or diluents.

15. (Amended) A method for the treatment or prophylaxis of HBV infection said method comprising administering to a subject an amount of a variant HBV or variant HbsAg according to any one of claims 1 to 12 [or a composition according to claim 13 or 14], said amount being effective to induce an immune response to said variant HBV.

PHIP\298317\1